Not all these cases meet the definition of AML with BCR::ABL1 since BCR::ABL1 acts as a secondary event and is likely to confer a proliferative advantage, such as NRAS, FLT3, or KIT mutations. The gene discussed is FLT3; the disease is acute myeloid leukemia.